血小板衍生生长因子在局灶节段性肾小球硬化中的作用
研究在Thy1.1转基因小鼠、5/6肾切除小鼠、Col4-/-(Alport)小鼠、患者肾活检及原代小鼠壁上皮细胞中探讨PDGF-B/PDGFR-β在FSGS中的作用。发现PDGF-B在足细胞上调、PDGFR-β在壁上皮细胞上调,中和抗体改善肾功能并减少FSGS及壁上皮细胞增殖。结论认为PDGF-B-PDGFR-β分子串话驱动肾小球硬化和FSGS进展。
要点
- PDGF-B在FSGS足细胞中上调,PDGFR-β在壁上皮细胞中上调。
- 抗PDGF-B中和抗体改善肾功能并减少FSGS和壁上皮细胞增殖。
- PDGF-B刺激原代小鼠壁上皮细胞可重现体内激活和增殖,可被PDGF-B抗体或伊马替尼抑制。
核心结论
- PDGF-B-PDGFR-β分子串话驱动肾小球硬化和FSGS进展。
研究设计与样本
- 研究使用经抗Thy1.1抗体攻击的Thy1.1转基因小鼠(足细胞表达Thy1.1)、5/6肾切除小鼠、Col4-/-(Alport)小鼠、患者肾活检、原代小鼠壁上皮细胞,以及接受抗PDGF-B中和抗体治疗的攻击Thy1.1小鼠。
主要发现
- 未攻击的Thy1.1小鼠仅发生轻度自发性FSGS,而攻击后小鼠发生进行性FSGS并伴肾功能下降。
- 壁上皮细胞活化、增殖和促纤维化表型转化驱动FSGS。
- 疾病过程中PDGF-B在足细胞上调,PDGFR-β在来自小鼠和FSGS患者的壁上皮细胞上调。
- 短期和长期抗PDGF-B中和抗体治疗改善肾功能并减少FSGS、壁上皮细胞增殖和促纤维化活化。
- 体外PDGF-B刺激原代小鼠壁上皮细胞重现体内壁上皮细胞活化和增殖,可被PDGF-B抗体或伊马替尼抑制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: FSGS is the final common pathway to nephron loss in most forms of severe or progressive glomerular injury. Although podocyte injury initiates FSGS, parietal epithelial cells (PECs) are the main effectors. Because PDGF takes part in fibrotic processes, we hypothesized that the ligand PDGF-B and its receptor PDGFR- β participate in the origin and progression of FSGS. METHODS: We challenged Thy1.1 transgenic mice, which express Thy1.1 in the podocytes, with anti-Thy1.1 antibody to study the progression of FSGS. We investigated the role of PDGF in FSGS using challenged Thy1.1 mice, 5/6 nephrectomized mice, Col4 -/- (Alport) mice, patient kidney biopsies, and primary murine PECs, and challenged Thy1.1 mice treated with neutralizing anti-PDGF-B antibody therapy. RESULTS: The unchallenged Thy1.1 mice developed only mild spontaneous FSGS, whereas challenged mice developed progressive FSGS accompanied by a decline in kidney function. PEC activation, proliferation, and profibrotic phenotypic switch drove the FSGS. During disease, PDGF-B was upregulated in podocytes, whereas PDGFR- β was upregulated in PECs from both mice and patients with FSGS. Short- and long-term treatment with PDGF-B neutralizing antibody improved kidney function and reduced FSGS, PEC proliferation, and profibrotic activation. In vitro , stimulation of primary murine PECs with PDGF-B recapitulated in vivo findings with PEC activation and proliferation, which was inhibited by PDGF-B antibody or imatinib. CONCLUSION: PDGF-B-PDGFR- β molecular crosstalk between podocytes and PECs drives glomerulosclerosis and the progression of FSGS. PODCAST: This article contains a podcast at.
引用
- Jia T, Xu T, Smeets B, et al. The Role of Platelet-Derived Growth Factor in Focal Segmental Glomerulosclerosis. J Am Soc Nephrol. 2022. PMID: 36351762. doi:10.1681/ASN.2022040491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。